
  
    
      
        Kinase_NNP Inhibition_NNP for_IN Treatment_NNP of_IN Cancer_NNP
        Uncontrolled_NNP proliferation_NN of_IN tumor_NN cells_NNS is_VBZ a_DT hallmark_NN of_IN cancer_NN ._. In_IN many_JJ types_NNS of_IN
        cancer_NN ,_, mutations_NNS in_IN genes_NNS that_WDT activate_VBP cellular_JJ signal_NN transduction_NN pathways_NNS contribute_VBP
        to_TO enhanced_JJ proliferation_NN and_CC survival_NN of_IN cancer_NN cells_NNS ._. One_CD well-characterized_JJ example_NN is_VBZ
        mutation_NN in_IN tyrosine_NN kinases_NNS ,_, enzymes_NNS that_WDT regulate_VB the_DT growth_NN and_CC survival_NN of_IN cells_NNS ._.
        Tyrosine_NNP kinase_NN activity_NN is_VBZ tightly_RB regulated_VBN in_IN normal_JJ cells_NNS ,_, but_CC is_VBZ dysregulated_JJ due_NN to_TO
        mutation_NN in_IN some_DT cancers_NNS ,_, including_VBG lung_NN cancer_NN ,_, resulting_VBG in_IN enhanced_JJ proliferation_NN and_CC
        survival_NN of_IN cancer_NN cells_NNS ._. The_DT tyrosine_NN kinases_NNS are_VBP attractive_JJ candidates_NNS for_IN molecularly_RB
        targeted_VBN therapy_NN in_IN cancer_NN ,_, because_IN cancers_NNS become_VBP dependent_JJ on_IN growth_NN signals_NNS from_IN the_DT
        mutant_JJ tyrosine_NN kinases_NNS ._. Tyrosine_NNP kinases_NNS require_VBP ATP_NNP for_IN their_PRP$ enzymic_JJ activity_NN ,_, and_CC thus_RB
        small_JJ molecules_NNS that_WDT mimic_VBP ATP_NNP can_MD bind_NN to_TO mutant_JJ kinases_NNS and_CC inactivate_NN them_PRP ._.
        The_DT paradigm_NN for_IN tyrosine_NN kinase_NN inhibition_NN as_IN treatment_NN for_IN cancer_NN using_VBG small-molecule_JJ
        inhibitors_NNS was_VBD first_RB established_VBN in_IN the_DT context_NN of_IN chronic_JJ myelogenous_JJ leukemia_NN (_( CML_NNP )_)
        associated_VBN with_IN the_DT 
        BCR-ABL_NNP gene_NN rearrangement_NN [_NN 1_CD ]_NN ._. Imatinib_NNP (_( Gleevec_NNP )_) ,_, a_DT
        2_CD -_: phenylaminopyrimidine_NN ,_, is_VBZ a_DT competitive_JJ inhibitor_NN of_IN ATP_NNP binding_VBG to_TO the_DT ABL_NNP kinase_NN ,_,
        thereby_RB inhibiting_VBG the_DT constitutively_RB activated_VBN BCR-ABL_NNP tyrosine_NN kinase_NN ._. Imatinib_NNP induces_VBZ
        complete_JJ remission_NN in_IN most_JJS patients_NNS with_IN CML_NNP in_IN stable_JJ phase_NN [_NN 1_CD ]_NN ,_, and_CC also_RB has_VBZ activity_NN in_IN
        CML_NNP that_WDT has_VBZ progressed_VBN to_TO blast_VB crisis_NN [_NN 2_CD ]_NN ._.
        Imatinib_NNP is_VBZ also_RB a_DT potent_JJ inhibitor_NN of_IN the_DT ARG_NNP ,_, KIT_NNP ,_, PDGFRA_NNP ,_, and_CC PDGFRB_NNP tyrosine_NN
        kinases_NNS ._. As_IN a_DT consequence_NN ,_, there_EX have_VBP been_VBN additional_JJ dividends_NNS from_IN the_DT United_NNP States_NNPS
        Federal_NNP Drug_NNP Administration_NNP approval_NN of_IN imatinib_NN for_IN treatment_NN of_IN BCR-ABL-positive_NNP CML_NNP ._. For_IN
        example_NN ,_, imatinib_NN is_VBZ effective_JJ in_IN treatment_NN of_IN chronic_JJ myelomonocytic_JJ leukemia_NN with_IN gene_NN
        rearrangements_NNS that_WDT constitutively_RB activate_VBP 
        PDGFRB_NNP [_NN 3_CD ]_NN ,_, of_IN hypereosinophilic_JJ syndrome_NN with_IN activating_VBG mutations_NNS in_IN 
        PDGFRA_NNP [_NN 4_CD ]_NN ,_, and_CC of_IN gastrointestinal_NN stromal_NN cell_NN tumors_NNS associated_VBN with_IN
        activating_VBG mutations_NNS in_IN 
        KIT_NNP [_NN 5_CD ]_NN (_( all_DT reviewed_VBN in_IN [_NN 6_CD ]_NN )_) ._.
        More_RBR recently_RB ,_, this_DT paradigm_NN has_VBZ been_VBN extended_VBN to_TO treatment_NN of_IN non-small_JJ cell_NN lung_NN
        cancer_NN (_( NSCLC_NNP )_) ._. Several_JJ mutations_NNS have_VBP been_VBN identified_VBN in_IN the_DT context_NN of_IN 
        epidermal_NN growth_NN factor_NN receptor_NN (_( EGFR_NNP )_) in_IN patients_NNS with_IN NSCLC_NNP that_WDT are_VBP
        associated_VBN with_IN clinical_JJ response_NN to_TO the_DT small-molecule_JJ EGFR_NNP inhibitors_NNS gefitinib_NN (_( Iressa_NNP )_)
        or_CC erlotinib_NN (_( Tarceva_NNP )_) [_NN 7_CD ,_, 8_CD ,_, 9_CD ]_NN ,_, including_VBG in-frame_JJ deletions_NNS such_JJ as_IN del_FW L_NNP 747_CD –_NN E_NNP 749_CD ;_: A_DT 750_CD P_NN in_IN
        exon_NN 19_CD ,_, or_CC L_NNP 858_CD R_NN in_IN exon_NN 21_CD ._. Although_IN responses_NNS are_VBP often_RB dramatic_JJ ,_, most_JJS responding_VBG
        patients_NNS ultimately_RB develop_VBP clinical_JJ resistance_NN and_CC relapse_NN of_IN disease_NN [_NN 7_CD ,_, 8_CD ,_, 9_CD ]_NN ._. The_DT basis_NN
        for_IN resistance_NN had_VBD not_RB been_VBN known_VBN ,_, in_IN part_NN owing_VBG to_TO the_DT difficulty_NN in_IN obtaining_VBG tissue_NN from_IN
        re-biopsy_JJ at_IN time_NN of_IN relapse_NN ._.
      
      
        Resistance_NNP to_TO Small-_NNP Molecule_NNP Tyrosine_NNP Kinase_NNP Inhibitors_NNP
        As_IN might_MD have_VB been_VBN anticipated_VBN in_IN treatment_NN of_IN cancer_NN with_IN any_DT single_JJ agent_NN ,_, resistance_NN
        to_TO small-molecule_JJ tyrosine_NN kinase_NN inhibitors_NNS has_VBZ emerged_VBN as_IN a_DT significant_JJ clinical_JJ problem_NN ._.
        This_DT was_VBD first_RB appreciated_VBN in_IN patients_NNS with_IN CML_NNP treated_VBD with_IN imatinib_NN whose_WP$ tumors_NNS
        developed_VBD resistance_NN ,_, and_CC has_VBZ been_VBN most_RBS extensively_RB studied_VBN in_IN that_DT context_NN ._. Although_IN there_EX
        are_VBP many_JJ potential_JJ mechanisms_NNS for_IN development_NN of_IN clinical_JJ resistance_NN ,_, most_JJS cases_NNS of_IN
        imatinib-resistant_JJ CML_NNP are_VBP due_JJ to_TO point_VB mutations_NNS in_IN the_DT 
        BCR-ABL_NNP kinase_NN domain_NN itself_PRP ,_, including_VBG T_NN 315_CD I_PRP [_NN 10_CD ,_, 11_CD ]_NN ._. Similar_JJ mutations_NNS
        in_IN the_DT homologous_RB residues_NNS of_IN the_DT kinase_NN domains_NNS of_IN PDGFRA_NNP (_( T_NN 674_CD I_PRP )_) and_CC KIT_NNP (_( T_NN 670_CD I_PRP )_) account_NN
        for_IN imatinib_NN resistance_NN in_IN some_DT patients_NNS with_IN hypereosinophilic_JJ syndrome_NN and_CC
        gastrointestinal_NN stromal_NN cell_NN tumors_NNS ,_, respectively_RB [_NN 4_CD ,_, 12_CD ]_NN ._. These_DT findings_NNS suggest_VBP
        strategies_NNS to_TO overcome_VB resistance_NN that_WDT include_VBP the_DT use_NN of_IN alternative_NN small-molecule_JJ
        inhibitors_NNS ._. Indeed_RB ,_, about_IN three_CD years_NNS after_IN the_DT recognition_NN of_IN imatinib_NN resistance_NN
        mutations_NNS in_IN BCR-ABL-positive_NNP CML_NNP ,_, new_JJ drugs_NNS are_VBP now_RB in_IN clinical_JJ trials_NNS that_WDT are_VBP potent_JJ
        inhibitors_NNS of_IN imatinib-resistant_JJ BCR-ABL_NNP mutants_NNS [_NN 13_CD ,_, 14_CD ]_NN ._.
      
      
        A_DT Basis_NNP for_IN Resistance_NNP to_TO Small-_NNP Molecule_NNP EGFR_NNP Inhibitors_NNP in_IN NSCLC_NNP
        In_IN an_DT elegant_JJ new_JJ study_NN in_IN 
        PLoS_NNP Medicine_NNP ,_, Pao_NNP and_CC colleagues_NNS have_VBP identified_VBN acquired_VBN mutations_NNS in_IN
        patients_NNS with_IN NSCLC_NNP that_WDT appear_VBP to_TO explain_VB clinical_JJ resistance_NN to_TO gefitinib_NN or_CC erlotinib_NN
        [_NN 15_CD ]_NN ._. The_DT mechanism_NN of_IN resistance_NN in_IN three_CD patients_NNS was_VBD acquisition_NN of_IN a_DT T_NN 790_CD M_NNP substitution_NN
        in_IN EGFR_NNP that_WDT was_VBD not_RB present_JJ at_IN time_NN of_IN diagnosis_NN ,_, but_CC was_VBD detected_VBN with_IN progression_NN of_IN
        disease_NN after_IN initial_JJ response_NN to_TO gefitinib_NN or_CC erlotinib_NN ._. T_NN 790_CD M_NNP in_IN the_DT context_NN of_IN either_DT
        transiently_RB expressed_VBD wild-type_JJ EGFR_NNP or_CC the_DT mutant_JJ alleles_NNS del_FW L_NNP 474_CD –_NN E_NNP 749_CD ;_: A_DT 750_CD P_NN or_CC L_NNP 858_CD R_NN
        impairs_NNS inhibition_NN by_IN gefitinib_NN or_CC erlotinib_NN as_IN assessed_VBN by_IN autophosphorylation_NN ._.
        Furthermore_RB ,_, the_DT NSCLC_NNP cell_NN line_NN H_NNP 1975_CD harbors_NNS both_DT the_DT L_NNP 858_CD R_NN and_CC T_NN 790_CD M_NNP mutations_NNS ,_, and_CC is_VBZ
        resistant_JJ to_TO inhibition_NN by_IN gefitinib_NN or_CC erlotinib_NN ,_, unlike_IN cell_NN lines_NNS that_WDT express_VBP the_DT L_NNP 858_CD R_NN
        allele_NN alone_RB ._. In_IN the_DT H_NNP 1975_CD cell_NN line_NN ,_, it_PRP was_VBD possible_JJ to_TO obtain_VB adequate_JJ quantities_NNS of_IN RNA_NNP
        to_TO confirm_VB that_IN the_DT L_NNP 858_CD R_NN and_CC T_NN 790_CD M_NNP mutations_NNS are_VBP present_JJ on_IN the_DT same_JJ allele_NN ,_, as_IN would_MD be_VB
        predicted_VBN if_IN T_NN 790_CD M_NNP confers_VBZ resistance_NN to_TO inhibition_NN of_IN the_DT L_NNP 858_CD R_NN allele_NN ._.
        Structural_JJ models_NNS of_IN EGFR_NNP provide_VB structural_JJ insights_NNS into_IN these_DT biological_JJ data_NN ._. A_DT
        ribbon_NN structure_NN of_IN erlotinib_NN bound_VBN to_TO the_DT EGFR_NNP kinase_NN domain_NN (_( Figure_NN 1_LS )_) shows_VBZ the_DT
        threonine_NN residue_NN at_IN position_NN 790_CD in_IN green_JJ and_CC the_DT positions_NNS of_IN the_DT exon_NN 19_CD and_CC L_NNP 858_CD R_NN
        gain-of-function_JJ mutations_NNS ._. Substitution_NNP of_IN methionine_NN for_IN threonine_NN at_IN position_NN 790_CD would_MD
        be_VB predicted_VBN to_TO result_VB in_IN steric_JJ hindrance_NN of_IN erlotinib_NN binding_JJ to_TO EGFR_NNP (_( Figure_NN 2_LS )_) ._.
        These_DT observations_NNS provide_VBP convincing_JJ evidence_NN that_IN ,_, at_IN least_JJS in_IN some_DT patients_NNS with_IN
        NSCLC_NNP ,_, resistance_NN to_TO gefitinib_NN or_CC erlotinib_NN can_MD be_VB attributed_VBN to_TO acquisition_NN of_IN a_DT T_NN 790_CD M_NNP
        mutation_NN in_IN the_DT context_NN of_IN EGFR_NNP ._. However_RB ,_, three_CD additional_JJ patients_NNS with_IN clinical_JJ
        resistance_NN to_TO gefitinib_NN or_CC erlotinib_NN did_VBD not_RB have_VB the_DT T_NN 790_CD M_NNP mutation_NN ,_, nor_CC did_VBD they_PRP have_VB
        mutant_JJ 
        KRAS_NNP alleles_NNS that_WDT have_VBP previously_RB been_VBN shown_VBN by_IN these_DT same_JJ authors_NNS to_TO
        confer_VB resistance_NN to_TO these_DT inhibitors_NNS [_NN 9_CD ]_NN ._. Thus_RB ,_, mechanisms_NNS of_IN resistance_NN are_VBP
        heterogeneous_JJ ._.
      
      
        Next_JJ Steps_NNS ,_, and_CC Lessons_NNP Learned_NNP
        It_PRP will_MD be_VB important_JJ to_TO identify_VB alternative_NN small-molecule_JJ inhibitors_NNS for_IN the_DT T_NN 790_CD M_NNP
        resistance_NN mutation_NN ._. Structural_JJ data_NNS suggest_VBP that_IN one_CD compound_NN ,_, lapatinib_NN ,_, may_MD subserve_NN
        this_DT purpose_NN [_NN 16_CD ]_NN ,_, but_CC it_PRP has_VBZ not_RB been_VBN tested_VBN for_IN biological_JJ activity_NN in_IN this_DT context_NN ._. New_JJ
        chemical_NN screens_NNS and_CC /_NN or_CC rational_JJ drug_NN design_NN to_TO identify_VB alternative_JJ inhibitors_NNS is_VBZ
        warranted_VBN ._. In_IN addition_NN ,_, only_RB half_NN of_IN this_DT small_JJ cohort_NN of_IN patients_NNS with_IN NSCLC_NNP with_IN clinical_JJ
        resistance_NN to_TO gefitinib_NN or_CC erlotinib_NN had_VBD the_DT T_NN 790_CD M_NNP substitution_NN ._. Efforts_NNS to_TO identify_VB
        alternative_JJ mechanisms_NNS for_IN resistance_NN may_MD be_VB guided_VBN by_IN experience_NN with_IN imatinib_NN resistance_NN
        in_IN the_DT context_NN of_IN BCR-ABL_NNP ,_, and_CC should_MD include_VB full-length_JJ sequencing_VBG of_IN EGFR_NNP to_TO identify_VB
        other_JJ resistance_NN mutations_NNS ,_, and_CC analysis_NN for_IN evidence_NN of_IN gene_NN amplification_NN ,_, as_RB well_RB as_IN
        investigation_NN of_IN other_JJ well-characterized_JJ mechanisms_NNS of_IN drug_NN resistance_NN such_JJ as_IN drug_NN efflux_NN
        or_CC increased_VBN drug_NN metabolism_NN ._.
        Pao_NNP and_CC colleagues_NNS '_POS superb_JJ study_NN also_RB highlights_VBZ several_JJ important_JJ points_NNS that_WDT may_MD guide_VB
        development_NN of_IN kinase-targeted_JJ therapies_NNS in_IN the_DT future_NN ._. It_PRP is_VBZ clear_JJ that_IN ,_, to_TO the_DT extent_NN
        that_IN small-molecule_JJ kinase_NN inhibitors_NNS are_VBP effective_JJ as_IN single_JJ agents_NNS in_IN treatment_NN of_IN
        cancer_NN ,_, resistance_NN will_MD develop_VB ._. Furthermore_RB ,_, based_VBN on_IN previous_JJ experience_NN ,_, some_DT of_IN these_DT
        patients_NNS are_VBP likely_JJ to_TO harbor_NN acquired_VBD point_NN mutations_NNS in_IN the_DT target_NN kinase_NN that_WDT confer_VBP
        resistance_NN ._. Resistance_NN mutations_NNS identified_VBN via_IN in_IN vitro_NN screens_NNS have_VBP shown_VBN a_DT high_JJ degree_NN
        of_IN correlation_NN with_IN those_DT that_WDT develop_VBP in_IN vivo_NN ,_, as_IN shown_VBN in_IN screens_NNS for_IN imatinib-resistant_JJ
        BCR-ABL_NNP mutants_NNS [_NN 11_CD ]_NN and_CC PKC_NNP 412_CD -_: resistant_JJ FLT_NNP 3_CD mutants_NNS [_NN 17_CD ]_NN ,_, as_RB well_RB as_IN the_DT T_NN 790_CD M_NNP
        resistance_NN mutation_NN to_TO gefitinib_NN in_IN the_DT context_NN of_IN EGFR_NNP [_NN 18_CD ]_NN ._. Thus_RB ,_, in_IN vitro_NN screens_NNS for_IN
        mutations_NNS that_WDT confer_VBP resistance_NN to_TO kinase_NN inhibitors_NNS are_VBP warranted_VBN ,_, followed_VBN by_IN efforts_NNS to_TO
        identify_VB drugs_NNS that_WDT overcome_VBP resistance_NN ._. This_DT proactive_JJ approach_NN should_MD shorten_VB the_DT time_NN
        frame_NN for_IN new_JJ drug_NN development_NN ._.
        These_DT findings_NNS also_RB emphasize_VBP the_DT critical_JJ need_NN for_IN re-biopsy_JJ of_IN patients_NNS with_IN cancer_NN
        treated_VBN with_IN molecularly_RB targeted_VBN therapies_NNS at_IN time_NN of_IN relapse_NN ._. Tissue_NNP acquisition_NN is_VBZ more_JJR
        challenging_VBG in_IN solid_JJ tumors_NNS than_IN for_IN hematopoietic_JJ malignancies_NNS ,_, and_CC may_MD entail_VB risk_NN ._.
        Nonetheless_RB ,_, it_PRP is_VBZ clear_JJ that_IN data_NNS derived_VBN from_IN such_JJ analyses_NNS will_MD be_VB essential_JJ to_TO inform_VB
        approaches_NNS to_TO improving_VBG therapy_NN for_IN NSCLC_NNP and_CC other_JJ solid_JJ tumors_NNS ._.
      
    
  
